Novartis AG described the identification and activity of TAK-756, a novel, selective and potent TAK1 inhibitor, as a potential intra-articular therapy for the treatment of osteoarthritis. Previous ...
Press Release Temple OrthoBiologics, a new venture spun out from women's health company Temple Therapeutics, is proud to announce its official launch heralding a breakthrough in orthopedic sports ...